Gate Bioscience
Latest round
- Series B
Last raised
- Nov 2025
Total raised
- $125M
Investors
- 6
About Gate Bioscience
Based in California, US, and founded in 2021, Gate Bioscience, Inc. operates as a biotechnology company that develops drugs and provides small molecule drugs called Molecular Gates which eliminate extracellular proteins. The company was Co-founded by Jordi Mata (CEO), Pat Sharp, and Raman Talwar (CTO). In November 2025, Gate Bioscience, Inc. The firm develops small molecule therapeutics named molecular gates which are small molecule drugs that eliminate harmful extracellular proteins at their origin, inside cells, and prevent them from emerging to cause disease.
Who invested in Gate Bioscience
6 investors across 2 rounds
See all investors in Gate Bioscience
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Gate Bioscience
Who invested in Gate Bioscience?
Gate Bioscience has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Gate Bioscience raised?
Gate Bioscience has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Gate Bioscience last raise money?
Gate Bioscience's most recent round on record is a Series B, in Nov 2025.
What does Gate Bioscience do?
Based in California, US, and founded in 2021, Gate Bioscience, Inc.
Where is Gate Bioscience headquartered?
Gate Bioscience is headquartered in Brisbane, US.
Which VCs invest in companies like Gate Bioscience?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Gate Bioscience's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Gate Bioscience? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.